1Chase A J, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodeling[J]. J Vasc Res, 2003,40:329-343.
2Senzaki H, Masurtani S, Kobayashi J, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki diease [J]. Circulation, 2001,104:860-863.
3Chua PK, Melish ME, Yu Q, et al. Elevated levels of metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 during the acute phase of Kawasaki disease[J]. Clin Diagn Lab Immunol, 2003, 10(2):308-314.
4Gavin PJ, Crawford SE, Shulman ST, et al. Systemic arterial expression of matrix metalloproteinases 2 and 9 in Kawasaki disease [J]. Arterioscler Thromb Vasc Biol,2003,23: 576-581.
5Kato H, Sugimura T, Akagi T, et al. Long-term consequence of Kawasaki Disease: 10- to 21 year followup study of 594 patients[J]. Circulation, 1996,94:1379-1385.
6Christian R, Helmut K, Peto EP. Regulation if 92-KD gelatinase release in HL-60 leukemia cells:Tumor necrosis factor as an autocrine stimulus for basal-and phorbol ester induced secretion [J]. Blood,1994,83(12) :3638-3646.
7Furui J, Ishii M, Ikeda H, et al. Soluble forms of the selectin family in children with Kawasaki disease:prediction for coronary artery lesions [J]. Acta Paediatr,2002,91(11):1183-1188.
8Nakatani K, Takeshita S, Tsujimoto H, et al. Circulating endothelial cells in Kawasaki disease [J]. Clin Exp Immunol, 2003,131(3) :536-540.
9Takeshita S,Tokutomi T,Kawase H,et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease [J]. Clin Exp Immunol, 2001,125:340-344.
10Hovsepian DM, Ziporin SJ, Sakurai MK, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms:a circulating markers of degenerative aneurysm disease [J]. J Vasc Interv Radiol,2000,11:1345-1352.
